RBC Capital analyst Luca Issi raised the firm’s price target on Ascendis Pharma (ASND) to $230 from $210 and keeps an Outperform rating on the shares. The company posted another strong beat for Yorvipath despite some FX headwinds while prescriber base also expanded from 1,000 to 1,750 docs, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma price target raised to $307 from $306 at UBS
- Ascendis Pharma price target raised to $290 from $243 at Citi
- Ascendis Pharma price target raised to $295 from $289 at Wells Fargo
- Ascendis Pharma’s Promising Growth Trajectory: Buy Rating Affirmed Amid Strong Yorvipath Performance and Strategic Pipeline Developments
- Ascendis Pharma Reports Strong Q2 2025 Growth